A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids)

NCT05526521 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Spontaneous Urticaria

Interventions

DRUG: Dupilumab

Sponsor

Sanofi